(Q38753554)

6 September 2017

title

Safety and tolerability of pneumococcal vaccines in children (English)

1 reference

6 September 2017

1 reference

1

1 reference

6 September 2017

2

Nicola Principi

1 reference

6 September 2017

language of work or name

English

0 references

publication date

27 February 2016

1 reference

Expert Opinion on Drug Safety

6 September 2017

published in

1 reference

6 September 2017

volume

15

1 reference

6 September 2017

issue

6

1 reference

6 September 2017

page(s)

777-785

1 reference

Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

A century of pneumococcal vaccination research in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association betw

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

International trends in sudden infant death syndrome: stabilization of rates requires further action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Serotype-independent pneumococcal vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness☆☆☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1160056

10.1517/14740338.2016.1160056

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference